Targeting TGF-β1 as a therapeutic approach still remains challenging and our findings now provide the encouragement to study TGF-β2 as an alternative promising target for the treatment of liver fibrosis and HCC. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.